Economy forces consumers to cut back on health care
KANSAS CITY, Mo. According to a survey conducted by the National Association of Insurance Commissioners, American are cutting back on health care as a way to save money in today’s economy, as reported by The Washington Business Journal.
Nearly a quarter of the 686 consumers polled across the U.S. said they have reduced the number of visits they take to a doctor as a result of the rough economy. Also, 11 percent said they have scaled back on the number of prescription medications they take or the dosage of medications to make the prescription last longer.
Despite the cutbacks in healthcare spending, the association’s July 2008 survey revealed 85 percent of the respondents have not reduced, cancelled or made changes to their insurance policies.
ActivePHR wins CDHC award
NEW YORK ActivePHR, ActiveHealth Management’s personal health record has been named a winner of the 2008 Consumer Driven Health Care Solutions Award for Most Effective Solution Provider, as awarded by CDHC Solutions magazine.
The ActivePHR program provides an electronic home for a person’s health information. ActivePHR generates actionable alerts when opportunities to improve care are identified. Other innovative features within ActivePHR include integration with ActiveHealth’s health risk assessment and disease management program, the ability to grant access to doctors/caregivers, health trackers, calendar, and translation to Spanish.
“Consumers need and want to take an increased role in their healthcare,” said Peter Neupert, corporate vice president of Microsoft Health Solutions Group. “A personal health record like ActivePHR empowers consumers. When consumers have the ability to present a complete picture of their health and information on specific issues to all of their doctors and caregivers, the result is better care.”
Danish company finds potential weight-loss drug
NEW YORK Good results from a study of a new drug from Denmark-based NeuroSearch caused the company’s stock to increase the most in more than a month, according to Bloomberg.
Studies of the experimental drug tesofensine showed that it improved fat metabolism and lowered weight. The results caused NeuroSearch’s stock to rise by about $2.20 to $50.77, a 4.5 percent increase.
The drug company said it hoped to find a partner to fund the testing required to gain regulatory approval for the drug, which could generate $1.1 billion in sales if approved.
One dollar equaled 5 kroner, as of mid-day Tuesday.